MacroGenics, Inc. MGNX 深 滬
等待開盤 01-29 09:30:00 美东时间
1.815
-0.025
-1.36%
華盛通- 最 高1.8597
- 今 開1.84
- 成交量 40.69万股
- 最 低 1.80
- 昨 收 1.84
- 總市值 1.15亿
- 52周最高 2.95
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 0.9897
- 委 比 -71.33%
- 總股本 6320.57万
- 歷史最高 41.00
- 量 比 0.46
- 振 幅 3.24%
- 歷史最低 0.9897
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
2025-12-18 19:07
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
MacroGenics, Inc. announced that its President and CEO, Eric Risser, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4 at 7:55 am ET in Miami, FL. The presentation will be available via webcast under "Events & Presentations" on MacroGenics' Investor Relations website, with an archived replay for 30 days.
2025-11-25 21:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
2025-11-13 20:06
Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $(0.58) by 146.31 percent. This is a 70 percent decrease over earnings of $0.90 per share from the
2025-11-13 05:41
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
<p>MacroGenics首席执行官Eric Risser将参加Stifel 2025医疗健康大会炉边谈话。活动时间为2025年11月13日纽约下午4点。网络直播及其存档可在公司投资者关系页面访问。</p>
2025-11-06 21:30
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.
2025-11-03 20:02
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
MacroGenics, Inc. announced that CEO Eric Risser will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:30am ET in New York. A webcast will be available under "Events & Presentations" on the Company's website, with a 30-day replay. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer, utilizing proprietary technology platforms and collaborating with global pharmaceut...
2025-09-02 20:30
MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors?
MacroGenics Inc (($MGNX)) announced an update on their ongoing clinical study. ...
2025-08-15 00:27
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
MacroGenics reported Q2 2025 financial results with a cash position of $176.5M, up from $134.9M in Q2 2024, and highlighted strategic priorities for lorigerlimab, MGC026/MGC028 advancement, IND submissions, and partnerships. Notably, they received a $70M upfront payment from Sagard for ZYNYZ and aim to enhance operational efficiency to improve financial position.
2025-08-14 20:01
